T H Acciani1,2, T Suzuki1,2,3, B C Trapnell1,2,3,4,5, T D Le Cras1,2. 1. Division of Pulmonary Biology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 2. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 3. Translational Pulmonary Science Center, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 4. Division of Pulmonary Medicine, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 5. Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Abstract
BACKGROUND: Airway epithelial cells (AEC) are increasingly recognized as a major signalling centre in the pathogenesis of allergic asthma. A previous study demonstrated that epithelial growth factor receptor (EGFR) signalling in AEC regulated key features of allergic airway disease. However, it is unclear what mediators are regulated by EGFR signalling in AEC, although the production of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is EGFR dependent in keratinocytes. OBJECTIVES: To determine whether EGFR signalling regulates GM-CSF production by human AEC downstream of the clinically relevant mediators house dust mite (HDM) and interleukin (IL)-17A and in a mouse model of established allergic asthma. METHODS: EGFR inhibitors were used to determine whether EGFR signalling regulates GM-CSF production by cultured human AEC in response to HDM and IL-17A. The roles of EGFR ligands, p38 mitogen-activated protein kinase (MAPK) and tumour necrosis factor-alpha (TNF-α) converting enzyme (TACE) were also assessed. To determine whether EGFR regulates GM-CSF as well as key asthma characteristics in vivo, mice were chronically exposed to HDM to establish allergic airway disease and then treated with the EGFR inhibitor Erlotinib. RESULTS: EGFR inhibition reduced HDM and IL-17A induced GM-CSF production in a dose-dependent manner in cultured human AEC. GM-CSF production also required amphiregulin, p38 MAPK signalling and protease/TACE activity. In mice with established allergic airway disease, EGFR inhibition reduced levels of GM-CSF and TNF-α, as well as airway hyperreactivity, cellular inflammation, smooth muscle thickening and goblet cell metaplasia without changes in IgE and Th1, Th2 and Th17 cytokines. CONCLUSIONS AND CLINICAL RELEVANCE: Results link HDM, IL-17A, amphiregulin, EGFR and GM-CSF in a mechanistic pathway in AEC and demonstrate that EGFR regulates GM-CSF production and the severity of established disease in a clinically relevant asthma model. These results identify the EGFR→GM-CSF axis as a target for therapeutic development.
BACKGROUND: Airway epithelial cells (AEC) are increasingly recognized as a major signalling centre in the pathogenesis of allergic asthma. A previous study demonstrated that epithelial growth factor receptor (EGFR) signalling in AEC regulated key features of allergic airway disease. However, it is unclear what mediators are regulated by EGFR signalling in AEC, although the production of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is EGFR dependent in keratinocytes. OBJECTIVES: To determine whether EGFR signalling regulates GM-CSF production by human AEC downstream of the clinically relevant mediators house dust mite (HDM) and interleukin (IL)-17A and in a mouse model of established allergic asthma. METHODS:EGFR inhibitors were used to determine whether EGFR signalling regulates GM-CSF production by cultured human AEC in response to HDM and IL-17A. The roles of EGFR ligands, p38 mitogen-activated protein kinase (MAPK) and tumour necrosis factor-alpha (TNF-α) converting enzyme (TACE) were also assessed. To determine whether EGFR regulates GM-CSF as well as key asthma characteristics in vivo, mice were chronically exposed to HDM to establish allergic airway disease and then treated with the EGFR inhibitor Erlotinib. RESULTS:EGFR inhibition reduced HDM and IL-17A induced GM-CSF production in a dose-dependent manner in cultured human AEC. GM-CSF production also required amphiregulin, p38 MAPK signalling and protease/TACE activity. In mice with established allergic airway disease, EGFR inhibition reduced levels of GM-CSF and TNF-α, as well as airway hyperreactivity, cellular inflammation, smooth muscle thickening and goblet cell metaplasia without changes in IgE and Th1, Th2 and Th17 cytokines. CONCLUSIONS AND CLINICAL RELEVANCE: Results link HDM, IL-17A, amphiregulin, EGFR and GM-CSF in a mechanistic pathway in AEC and demonstrate that EGFR regulates GM-CSF production and the severity of established disease in a clinically relevant asthma model. These results identify the EGFR→GM-CSF axis as a target for therapeutic development.
Authors: Timothy D Le Cras; Thomas H Acciani; Elizabeth M Mushaben; Elizabeth L Kramer; Patricia A Pastura; William D Hardie; Thomas R Korfhagen; Umasundari Sivaprasad; Mark Ericksen; Aaron M Gibson; Michael J Holtzman; Jeffrey A Whitsett; Gurjit K Khurana Hershey Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-12-17 Impact factor: 5.464
Authors: Mab Pereira Corrêa; Frans Eberth Costa Andrade; Alexandre Dantas Gimenes; Cristiane Damas Gil Journal: J Mol Med (Berl) Date: 2017-06-29 Impact factor: 4.599
Authors: Jalahalli M Siddesha; Emily M Nakada; Bethany R Mihavics; Sidra M Hoffman; Gurkiranjit K Rattu; Nicolas Chamberlain; Jonathon M Cahoon; Karolyn G Lahue; Nirav Daphtary; Minara Aliyeva; David G Chapman; Dhimant H Desai; Matthew E Poynter; Vikas Anathy Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-05-06 Impact factor: 5.464
Authors: Tetsuya Homma; Atsushi Kato; Masafumi Sakashita; Tetsuji Takabayashi; James E Norton; Lydia A Suh; Roderick G Carter; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Jin-Young Min; Stephanie Shintani-Smith; Bruce K Tan; Kevin Welch; David B Conley; Robert C Kern; Robert P Schleimer Journal: Am J Respir Cell Mol Biol Date: 2017-09 Impact factor: 6.914
Authors: Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner Journal: J Clin Invest Date: 2019-01-14 Impact factor: 14.808
Authors: Mahmood Yaseen Hachim; Noha Mousaad Elemam; Rakhee K Ramakrishnan; Laila Salameh; Ronald Olivenstein; Ibrahim Yaseen Hachim; Thenmozhi Venkatachalam; Bassam Mahboub; Saba Al Heialy; Rabih Halwani; Qutayba Hamid; Rifat Hamoudi Journal: Front Med (Lausanne) Date: 2020-10-29
Authors: Avraham Unterman; Tomokazu S Sumida; Nima Nouri; Xiting Yan; Amy Y Zhao; Victor Gasque; Jonas C Schupp; Hiromitsu Asashima; Yunqing Liu; Carlos Cosme; Wenxuan Deng; Ming Chen; Micha Sam Brickman Raredon; Kenneth B Hoehn; Guilin Wang; Zuoheng Wang; Giuseppe DeIuliis; Neal G Ravindra; Ningshan Li; Christopher Castaldi; Patrick Wong; John Fournier; Santos Bermejo; Lokesh Sharma; Arnau Casanovas-Massana; Chantal B F Vogels; Anne L Wyllie; Nathan D Grubaugh; Anthony Melillo; Hailong Meng; Yan Stein; Maksym Minasyan; Subhasis Mohanty; William E Ruff; Inessa Cohen; Khadir Raddassi; Laura E Niklason; Albert I Ko; Ruth R Montgomery; Shelli F Farhadian; Akiko Iwasaki; Albert C Shaw; David van Dijk; Hongyu Zhao; Steven H Kleinstein; David A Hafler; Naftali Kaminski; Charles S Dela Cruz Journal: Nat Commun Date: 2022-01-21 Impact factor: 17.694